Roche Releases Positive Phase I Results for R1507
COPENHAGEN, October 23 /PRNewswire-FirstCall/ -- Genmab A/S (OMX: GEN) announced today positive results from a Phase I study of R1507 in patients with solid tumors, conducted by its partner Roche. R1507 is a human monoclonal antibody targeting the insulin-like growth factor receptor (IGF-1R) and was developed under Roche's collaboration with Genmab.
Nine of 34 adult patients with solid tumors experienced disease stabilization when treated with R1507. Four of the seven heavily pretreated patients with Ewing's sarcoma demonstrated clinical benefit with two of these patients achieving durable, objective partial responses.
Once a week administration of R1507 was well tolerated with few side effects. The most frequently observed side effects were fatigue, anorexia and weight loss, symptoms that are commonly observed in patients with advanced cancer. A similar side effect profile was seen in 26 patients who were treated with R1507 on a three week schedule.
The results were reported during the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics in San Francisco, California, USA. Further details can be found at http://www.rocheusa.com.
"These are the first clinical results to be presented from an antibody developed by Genmab under our collaboration with Roche," said Lisa N. Drakeman, Ph.D. "We are pleased with these positive results and hope it may offer a potential treatment for sarcoma patients in the future."
Based on these initial results with R1507, Roche plans to conduct additional trials and work with a global consortium of sarcoma experts, including the Sarcoma Alliance for Research through Collaboration (SARC).
IGF-1 is one of the most potent natural activators of the AKT and MAPK
signaling pathways, which promote cell growth and cell survival. The IGF-1R
|SOURCE Genmab A/S|
Copyright©2007 PR Newswire.
All rights reserved